IRB approval for DMI with administration of deuterium-labeled compounds in diabetes patients

IRB approval will be obtained for DMI with administration of deuterium-labeled compounds in type 2 diabetes patients. N=5 type 2 diabetes patients will be orally dosed with deuterated glucose for the measurement of glycogen synthesis in the liver. N=5 type 2 diabetes patients will be orally dosed with heavy water for the measurement of de novo lipogenesis in the liver.